Search research articles
Contact Us
Filters
Showing results (411-420 of 434) with videos related to
Page
of 44
Sort By:
Dermatology and Therapy
|
December 23, 2018
Clinical Goals and Barriers to Effective Psoriasis Care
Bruce E Strober, Joelle M van der Walt, April W Armstrong, et al.
Journal of Drugs in Dermatology : JDD
|
December 2, 2025
Report From the 2024 International Dermatology Outcome Measures (IDEOM) Annual Meeting
Sarah Romanelli, Gretchen D Ball, Arianna J Zhang, et al.
Journal of the American Academy of Dermatology
|
January 10, 2021
National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments
Joel M Gelfand, April W Armstrong, Stacie Bell, et al.
Journal of the American Academy of Dermatology
|
September 6, 2020
National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1
Joel M Gelfand, April W Armstrong, Stacie Bell, et al.
Journal of Drugs in Dermatology : JDD
|
December 4, 2024
International Dermatology Outcome Measures (IDEOM): A Report From the 2023 Annual Meeting
Arianna J Zhang, Gretchen Ball, Melissa P Zundell, et al.
Circulation. Cardiovascular Imaging
|
May 20, 2018
Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers: A Randomized Placebo-Controlled Trial
Nehal N Mehta, Daniel B Shin, Aditya A Joshi, et al.
Lancet (London, England)
|
September 21, 2025
Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials
Linda Stein Gold, April W Armstrong, Robert Bissonnette, et al.
The New England Journal of Medicine
|
October 1, 2015
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Mark Lebwohl, Bruce Strober, Alan Menter, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
January 11, 2016
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis
Laura C Coates, Arthur Kavanaugh, Philip J Mease, et al.
JAMA Network Open
|
January 16, 2019
Effectiveness of Online vs In-Person Care for Adults With Psoriasis: A Randomized Clinical Trial
April W Armstrong, Cindy J Chambers, Emanual Maverakis, et al.
Page
of 44
Search research articles
Search
Showing results (411-420 of 434) with videos related to
Sort By:
Page
of 44
Dermatology and Therapy
|
December 23, 2018
Clinical Goals and Barriers to Effective Psoriasis Care
Bruce E Strober, Joelle M van der Walt, April W Armstrong, et al.
Journal of Drugs in Dermatology : JDD
|
December 2, 2025
Report From the 2024 International Dermatology Outcome Measures (IDEOM) Annual Meeting
Sarah Romanelli, Gretchen D Ball, Arianna J Zhang, et al.
Journal of the American Academy of Dermatology
|
January 10, 2021
National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments
Joel M Gelfand, April W Armstrong, Stacie Bell, et al.
Journal of the American Academy of Dermatology
|
September 6, 2020
National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1
Joel M Gelfand, April W Armstrong, Stacie Bell, et al.
Journal of Drugs in Dermatology : JDD
|
December 4, 2024
International Dermatology Outcome Measures (IDEOM): A Report From the 2023 Annual Meeting
Arianna J Zhang, Gretchen Ball, Melissa P Zundell, et al.
Circulation. Cardiovascular Imaging
|
May 20, 2018
Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers: A Randomized Placebo-Controlled Trial
Nehal N Mehta, Daniel B Shin, Aditya A Joshi, et al.
Lancet (London, England)
|
September 21, 2025
Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials
Linda Stein Gold, April W Armstrong, Robert Bissonnette, et al.
The New England Journal of Medicine
|
October 1, 2015
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Mark Lebwohl, Bruce Strober, Alan Menter, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
January 11, 2016
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis
Laura C Coates, Arthur Kavanaugh, Philip J Mease, et al.
JAMA Network Open
|
January 16, 2019
Effectiveness of Online vs In-Person Care for Adults With Psoriasis: A Randomized Clinical Trial
April W Armstrong, Cindy J Chambers, Emanual Maverakis, et al.
Page
of 44